ResearchPUBMED4 days ago
Researchers in France studied a group of patients with myasthenia gravis (a rare disease where muscles become weak and tired easily) who were treated at special centers between 2007 and 2021. They collected information about these patients' backgrounds, how their disease developed, and how long they lived. This study helps doctors understand more about this disease and how to care for patients better.
WHY IT MATTERSThis registry data provides real-world evidence about myasthenia gravis outcomes and patient characteristics in France, which can help identify gaps in care and inform treatment guidelines for MG patients across Europe.
ResearchPUBMED5 days ago
Researchers in Germany studied health insurance records from 2017-2019 to understand how hemophilia A (a bleeding disorder) affects patients and how much it costs to treat. They found 257 patients with hemophilia A and grouped them by severity—mild, moderate, or severe—based on how much clotting medicine they needed. This study shows that insurance data can help doctors and researchers learn more about rare diseases like hemophilia A.
WHY IT MATTERSIf you have hemophilia A in Germany, this research demonstrates that your health insurance claims data can be used to better understand disease patterns, treatment costs, and care gaps—potentially leading to improved healthcare planning and resource allocation for your condition.
ResearchPUBMED5 days ago
Linear interstitial keratitis (LIK) is a very rare eye condition where a thin line of cloudiness forms in the clear part of the eye (the cornea). This study looked at 6 patients with this condition to better understand what it looks like, how doctors can diagnose it, and what treatments work best. The researchers found that the cloudy line usually appears near the edge of the cornea and can be seen clearly with special eye imaging tools.
WHY IT MATTERSThis is the largest study to date on linear interstitial keratitis, providing eye doctors with new guidance on diagnosis and treatment options for a condition that previously had no agreed-upon management approach.
Clinical trialCLINICALTRIALS5 days ago
Researchers are looking for patients with advanced lung cancer (stage III) that cannot be removed with surgery and has unusual genetic mutations. The study will test whether giving patients targeted drugs based on their specific genetic mutation, followed by surgery, works better than standard treatment. About 120 patients will participate in this research.
WHY IT MATTERSIf you have unresectable stage III NSCLC with a rare mutation, this trial offers access to personalized treatment tailored to your specific genetic profile before surgery—an approach not yet widely available outside research settings.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for Fabry disease patients is currently closed and not accepting new applications. Fabry disease is a rare genetic condition where the body can't break down certain fatty substances, causing problems in the heart, kidneys, and nerves. If you need help paying for Fabry disease treatment, you'll need to check back later or explore other assistance programs.
WHY IT MATTERSIf you have Fabry disease and were counting on PAN Foundation's copay assistance or medication support, you'll need to find alternative financial resources immediately since this program is not currently accepting applications.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for sickle cell disease patients is currently closed and not accepting new applications. This program helps patients pay for medications and treatment costs related to sickle cell disease. You can check the PAN Foundation website to find out when the program reopens or to explore other assistance options.
WHY IT MATTERSIf you have sickle cell disease and were counting on PAN Foundation's copay assistance, you'll need to find alternative financial support resources immediately, as this major assistance program is not currently accepting applications.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for phenylketonuria (PKU) — a rare genetic condition where the body can't break down a protein called phenylalanine — is currently closed. This program normally helps patients pay for treatment costs. The fund status changed on April 20, 2026.
WHY IT MATTERSIf you have PKU and were relying on PAN Foundation assistance to afford your medical care or special diet, you need to find alternative financial resources immediately since this program is no longer accepting applications.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for people with Spinal Muscular Atrophy (SMA) is currently closed and not accepting new applications. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them. You can check the program website to see when it reopens or find other financial help options.
WHY IT MATTERSIf you have SMA and struggle to afford your treatment, knowing this fund is temporarily closed helps you explore alternative financial assistance programs before your medication runs out.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for Gaucher disease patients is currently closed and not accepting new applications. Gaucher disease is a genetic condition where the body can't break down certain fatty substances, causing organ damage. The PAN Foundation helps patients pay for medications and treatment costs when they can't afford them otherwise.
WHY IT MATTERSIf you have Gaucher disease and need help paying for your treatment, you'll need to find alternative financial assistance programs since this major funding source is temporarily unavailable.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for Duchenne muscular dystrophy patients is currently closed and not accepting new applications. This program previously helped patients pay for medications and treatment costs related to this serious muscle disease. You can check the PAN Foundation website to see when the program reopens or explore other financial assistance options.
WHY IT MATTERSIf you have Duchenne muscular dystrophy and need help paying for medications or treatments, you'll need to find alternative financial assistance programs since this particular fund is not currently accepting applications.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for hereditary angioedema (HAE) is currently closed and not accepting new applications. Hereditary angioedema is a rare genetic condition that causes sudden swelling in the face, throat, hands, feet, and digestive system. Patients who need help paying for HAE treatment should check back at the foundation's website or contact them directly to learn when the program might reopen.
WHY IT MATTERSIf you have hereditary angioedema and struggle to afford medications or treatment, this closed fund means you'll need to explore alternative financial assistance programs or payment plans with your healthcare provider right now.
NewsUNITERARE6 days ago
The PAN Foundation's financial assistance program for cystic fibrosis patients is currently closed and not accepting new applications. This program helps patients pay for CF medications and treatments. You can check the PAN Foundation website to see when the fund reopens or to get on a waitlist.
WHY IT MATTERSIf you have cystic fibrosis and struggle to afford your medications, you'll need to find alternative financial assistance programs or contact your healthcare provider about other options while this fund is closed.
ResearchPUBMED6 days ago
Researchers in New Zealand interviewed 15 people with rare diseases and their caregivers to understand what it's like to get diagnosed and treated. They found that patients often have to fight hard to get answers and support because doctors don't know much about rare diseases. The study shows that people with rare diseases face similar challenges, even though their specific conditions are very different.
WHY IT MATTERSThis research directly documents the real-world barriers that rare disease patients face in accessing diagnosis and care in New Zealand, providing evidence that could help healthcare systems improve support for the estimated 300 million people worldwide living with rare disorders.
Clinical trialCLINICALTRIALS6 days ago
Researchers are looking for adults and children with certain immune system disorders to join a study. The immune system normally helps your body fight infections, but in some people it doesn't work properly, causing frequent infections and other health problems. This study wants to understand why some immune systems fail and how to help people with these conditions. Relatives of affected people may also be able to join.
WHY IT MATTERSThis trial is actively recruiting 500 participants with four specific genetic immune disorders (PI3KCD, CTLA4, STAT3GOF, and MAGT1 deficiency) — if you or a family member has one of these diagnoses, you may be eligible to enroll now and contribute to understanding these rare conditions.
Clinical trialCLINICALTRIALS6 days ago
Williams syndrome is a rare genetic condition that affects about 1 in every 8,000 to 12,000 people. It happens when a person is missing a small section of DNA on chromosome 7, which includes the gene that makes elastin (a protein that helps blood vessels stretch). This causes distinctive facial features and heart and blood vessel problems. Researchers are now recruiting 1,099 people with Williams syndrome or a related heart condition called supravalvular aortic stenosis to donate DNA and tissue samples to help scientists better understand these conditions.
WHY IT MATTERSThis actively recruiting biobank offers Williams syndrome and SVAS patients a direct way to contribute DNA and tissue samples to NHLBI-sponsored research that could accelerate understanding of the genetic causes and lead to new treatments.
PolicyRSS6 days ago
The FDA announced it has completed its first year of goals to reduce the use of animals in drug testing. The agency launched several new programs to replace animal testing with alternative methods that are often faster and more accurate. This shift means new medicines can be developed and tested in ways that don't require testing on animals.
WHY IT MATTERSFaster, more reliable drug testing methods could accelerate the development and approval of treatments for rare diseases, potentially bringing new therapies to patients years sooner than traditional animal testing timelines allow.
ResearchBIORXIVApr 20
Researchers analyzed blood samples from over 5,400 people with rare genetic diseases to see if a test called RNA-Seq could help find the genetic cause of their conditions. They found that this blood test works better for some diseases than others, and they used special computer programs to spot unusual gene activity patterns that might explain why people got sick. This study shows that blood tests could be a useful tool to help diagnose rare diseases alongside other genetic tests.
WHY IT MATTERSIf you have an undiagnosed rare disease, this research suggests blood-based RNA testing could help identify the genetic cause—potentially leading to a diagnosis after years of searching.
ResearchBIORXIVApr 20
Researchers studied blood samples from children with dengue virus infection to find early warning signs that could predict who will develop severe disease. By analyzing proteins in the blood, they identified markers related to inflammation and blood vessel damage that appear in children who get sicker. This discovery could help doctors quickly identify which children need more intensive care.
WHY IT MATTERSIf validated, these protein markers could enable doctors to predict dengue severity within hours of diagnosis in children, allowing earlier intervention before complications like hemorrhagic fever or shock develop.
ResearchBIORXIVApr 18
Researchers studied blood proteins in over 2,400 older adults to find which ones might predict memory and thinking problems later in life. They found 34 proteins linked to faster decline in orientation (knowing where you are and what time it is) and 18 proteins linked to memory loss over 15 years. This early-stage research could help doctors identify people at risk for dementia before symptoms appear.
WHY IT MATTERSIf validated, these protein signatures could enable blood tests to identify people at risk for cognitive decline years before symptoms develop, potentially opening windows for preventive treatments in Alzheimer's disease and related dementias.
ResearchCLINICALTRIALSApr 17
Researchers completed a study that collected information about how Canavan disease develops and progresses in children. The study looked at medical records from 67 patients and also gathered new information about their movement abilities and important health milestones. This type of study helps doctors understand the disease better and can guide future treatment development.
WHY IT MATTERSThis completed natural history study provides detailed data on how Canavan disease progresses in children, which is essential for designing future clinical trials and understanding what to expect from the disease.